BlueRock Therapeutics said it built an automated system for high-throughput auditing across cell therapy workflows, targeting a known gap between the rise of cell therapies and the availability of automation for analytical QC at small batch scales. The company’s approach accommodates cell culture, liquid handling, and processing with small-volume samples. The system is designed in collaboration with Hamilton Robotics and aims to reduce analytics costs by shrinking sample volumes required for testing, supporting faster execution as cell therapy programs scale toward commercial manufacturing. BlueRock positioned the tool as a bridge toward end-to-end audit processes that can be adapted across its pipeline programs. The announcement emphasizes high-throughput auditing rather than a clinical outcome claim, reflecting growing operational focus on manufacturing consistency and reproducible quality systems.